PAS
TEVA icon

Park Avenue Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Park Avenue Securities’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$650K Buy
19,191
+171
+0.9% +$5.7K ﹤0.01% 1169
2026
Q1 		$573K Buy
19,020
+7,845
+70% +$252K ﹤0.01% 1043
2025
Q4 		$349K Buy
11,175
+54
+0.5% +$1.33K ﹤0.01% 1252
2025
Q3 		$225K Buy
+11,121
New +$195K ﹤0.01% 1526
2025
Q2 		– Sell
-11,599
Closed -$178K – 1566
2025
Q1 		$178K Sell
11,599
-835
-7% -$14.9K ﹤0.01% 1135
2024
Q4 		$274K Buy
12,434
+2,341
+23% +$42.6K ﹤0.01% 1319
2024
Q3 		$182K Sell
10,093
-1,546
-13% -$27.1K ﹤0.01% 1349
2024
Q2 		$189K Sell
11,639
-5,936
-34% -$91.4K ﹤0.01% 1321
2024
Q1 		$248K Buy
+17,575
New +$222K ﹤0.01% 1244
2022
Q4 		– Sell
-11,850
Closed -$96K – 1218
2022
Q3 		$96K Buy
+11,850
New +$105K ﹤0.01% 1096

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Park Avenue Securities's TEVA Position: Q2 2026 in Review

Park Avenue Securities increased its Teva Pharmaceuticals (TEVA) stake by 0.9% in Q2 2026, buying an estimated $5.7K and bringing the position to 19,191 shares worth $650K. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Park Avenue Securities first reported a position in TEVA in Q3 2022 and has held it in 10 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Park Avenue Securities held 19,191 shares of Teva Pharmaceuticals worth $650K as of Q2 2026.
  • Park Avenue Securities bought 171 Teva Pharmaceuticals shares in Q2 2026, an estimated $5.7K.
  • Teva Pharmaceuticals made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1169 holding.
  • Park Avenue Securities first reported a position in Teva Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.